DIANA FRAHMAND: Open Payments
NPI 1104580679 · WOODBRIDGE, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,276 in 61 payments from 18 companies in 2025. Trend: 2023 $1,150 · 2024 $947 · 2025 $1,276
Food & beverage: $1,225Education: $51
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $273 |
| Janssen Biotech, Inc. | 9 | $149 |
| Gilead Sciences, Inc. | 2 | $141 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $134 |
| Ethicon US, LLC | 1 | $94 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $72 |
| Lilly USA, LLC | 3 | $66 |
| Ardelyx, Inc. | 3 | $65 |
| Celltrion USA Inc. | 2 | $57 |
| PFIZER INC. | 2 | $38 |
Products named: TREMFYA, RINVOQ, Livdelzi, XIFAXAN, LINX REFLUX MANAGEMENT SYSTEM, ENTYVIO, LINZESS, OMVOH.
Industry payments across VA — which companies pay providers there.
